Results 1 to 10 of about 234 (88)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer

Frontiers in Oncology, 2019
Introduction: Response to platinum-based therapy is a major prognostic factor in epithelial ovarian cancer (EOC) and reliable prognostic biomarkers are urgently needed to identify patients at high risk.
Paul Buderath, Esther Schwich, Christina Jensen   +2 more
exaly   +3 more sources

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma

Microorganisms, 2021
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy. The principal oncogene of EBV, latent membrane protein 1 (LMP1), induces the expression of programmed death-ligand 1 (PD-L1), which is an immunosuppressive transmembrane
Kina Kase, Satoru Kondo, Naohiro Wakisaka, Hirotomo Dochi, Harue Mizokami, Eiji Kobayashi, Makoto Kano, Takeshi Komori, Nobuyuki Hirai, Takayoshi Ueno, Yosuke Nakanishi, Miyako Hatano, Kazuhira Endo, Makiko Moriyama-Kita, Hisashi Sugimoto, Tomokazu Yoshizaki   +15 more
doaj   +1 more source

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Scientific Reports, 2023
The prognostic role of soluble PD-L1 (sPD-L1) and exosomal PD-L1 (exoPD-L1) in patients with gastric cancer (GC) receiving systemic chemotherapy remains unelucidated. Thus, we examined their prognostic significance in patients with advanced GC.
Kabsoo Shin, Joori Kim, Se Jun Park, Myung Ah Lee, Jae Myung Park, Myung-Gyu Choi, Donghoon Kang, Kyo Young Song, Han Hong Lee, Ho Seok Seo, Sung Hak Lee, Bohyun Kim, Okran Kim, Juyeon Park, Nahyeon Kang, In-Ho Kim   +15 more
doaj   +1 more source

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Discover Oncology, 2023
In this study, we explored the dynamic changes in blood sPD-L1 and its clinical value during anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) patients.
Ling Yi, Xiaojue Wang, Siyun Fu, Zhuohong Yan, Tianyu Ma, Siqi Li, Panjian Wei, Hongtao Zhang, Jinghui Wang   +8 more
doaj   +1 more source

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer

Journal of Translational Medicine, 2023
Background Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers.
Yinjun He, Xiang Zhang, Ming Zhu, Wenguang He, Hanju Hua, Feng Ye, Xile Zhou, Nan Chen, Yandong Li, Weixiang Zhong, Guosheng Wu, Hui Cai, Weiqin Jiang   +12 more
doaj   +1 more source

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Journal for ImmunoTherapy of Cancer, 2022
Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC ...
David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras   +9 more
doaj   +1 more source

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas

Frontiers in Oncology, 2020
Background: Soluble PD-L1 (sPD-L1) in the circulation has been documented to activate global immunosuppression and is considered a predictor of negative clinical outcomes in several malignances.
Shujun Liu, Shujun Liu, Yadi Zhu, Yadi Zhu, Chenxi Zhang, Chenxi Zhang, Xiangrui Meng, Xiangrui Meng, Bo Sun, Guojun Zhang, Guojun Zhang, Yubo Fan, Xixiong Kang, Xixiong Kang, Xixiong Kang   +14 more
doaj   +1 more source

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

OncoImmunology, 2017
Up to now, the efficacy of programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade in pancreatic cancer (PC) remains uncertain. Serum levels of soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have been reported to be independent prognostic ...
Stephan Kruger, Marie-Louise Legenstein, Verena Rösgen, Michael Haas, Dominik Paul Modest, Christoph Benedikt Westphalen, Steffen Ormanns, Thomas Kirchner, Volker Heinemann, Stefan Holdenrieder, Stefan Boeck   +10 more
doaj   +1 more source

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer

Brazilian Journal of Otorhinolaryngology, 2023
Objectives: The aim of the study was to investigate clinical significance of soluble PD-L1 (sPD-L1) serum level in head and neck cancer and to evaluate its role as a possible prognostic and predictive biomarker.
Maria Molga-Magusiak, Anna Rzepakowska, Michał Żurek, Iwona Kotuła, Urszula Demkow, Kazimierz Niemczyk   +5 more
doaj   +1 more source

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer

Endocrine Connections, 2019
To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed.
Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza, Navin Niles   +6 more
doaj   +1 more source